SciBase Partner With a Large Health Care Group in Los Angeles, Unified Health, and Receives a First Order
SciBase Partner With a Large Health Care Group in Los Angeles, Unified Health, and Receives a First Order
For additional information, please contact:STOCKHOLM, June 28, 2024 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), SciBase, a leading developer of augmented intelligence-based solutions for skin disorders announced today that it continues to expand in California with a collaboration agreement with Unified Health. Unified Health has nine clinics in Southern California.
2024年6月28日，瑞典斯德哥爾摩/PRNewswire——皮膚科技公司SciBase Holding AB（以下簡稱“SciBase”）（斯德哥爾摩證券交易所：SCIB）SciBase是一家領先的皮膚疾病增強智能解決方案開發商，宣佈今天與Unified Health達成合作協議，繼續在加利福尼亞州擴張。Unified Health在加州南部擁有九家診所。
"At Unified Health, we believe in providing our patients with exceptional medical care and access to the most advance medical technology. Our experienced team of providers are committed to delivering the highest quality of dermatological care to our patients, especially when it comes to the earliest detection possible of melanoma - the deadliest form of skin cancer. For these reasons, we are excited to use Nevisense and believe it will help us improve outcomes for our patients," says Michael Lin, MD, Board-Certified Dermatologist and Founder of Unified Health.
“在Unified Health，我們致力於爲患者提供卓越的醫療保健和最先進的醫療技術。我們有經驗豐富的醫生團隊致力於提供最高質量的皮膚病醫療保健，尤其是在病人早期發現黑色素瘤——最致命的皮膚癌症的情況下。因此，我們很高興使用Nevisense，並相信它將有助於提高病人的預後，”Unified Health的創始人和董事會認證皮膚科醫生邁克爾·林博士說。
"SciBase and Unified Health are well aligned with a shared mission to provide clinicians with early detection of melanoma solutions that can drive improved patient outcomes," says Pia Renaudin, CEO of SciBase. "We are encouraged to see more patients getting access to our point-of-care technology that enables the earliest detection possible of melanoma when it is almost 100% curable."
“SciBase和Unified Health的願景相同，目標是爲診所提供早期檢測黑色素瘤的解決方案，以推動改善患者預後，”SciBase的首席執行官皮亞·雷諾丹說。“我們很高興看到更多的病人獲得我們的門診技術，這使得我們能夠在黑色素瘤幾乎可以百分之百治癒的情況下儘早地進行檢測。”
For additional information, please contact:
Pia Renaudin, VD, tel. +46732069802, e-mail: [email protected]
欲了解更多信息，請聯繫:
Pia Renaudin，VD，電話+46 732069802，電子郵件：[email protected]
Certified Advisor (CA):
Vator Securities
Tel: +46 8 580 065 99
Email: [email protected]
認證顧問（CA）：
Vator Securities
電話：+46858006599
電子郵件：[email protected]
About SciBase:
關於SciBase：
SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to elevate diagnostic accuracy, ensuring proactive skin health management.
SciBase是一家全球性醫療技術公司，專注於皮膚疾病的早期檢測和預防。SciBase開發和商業化Nevisense，這是一種獨特的點對點平台，結合了人工智能和先進的電阻抗譜技術，提高了診斷準確性，確保積極的皮膚健康管理。
Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.
我們致力於減少患者的痛苦，使臨床醫生通過及時檢測和干預來改善和挽救生命，並降低醫療保健成本。
Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.
SciBase在瑞典斯德哥爾摩的卡羅林斯卡學院進行了20多年的研究，是皮膚病學進展的領先者。
The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015. Learn more at . All press releases and financial reports can be found here:
該公司自2015年6月2日在納斯達克創業板上市。請訪問了解更多信息。所有新聞發佈和財務報告都可以在此找到：
This information was brought to you by Cision
本信息由Cision提供
The following files are available for download:
以下文件可供下載：
|
PM_UH eng |
|
PM_UH eng |
譯文內容由第三人軟體翻譯。
